- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02472509
The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders
It is well established that hemolytic diseases predispose patients to the development of pigment gallstones. Gallstones are noted in at least 5% of children under the age of 10 years, increasing to 40-50% in the second to fifth decades. The co-inheritance of Gilbert's syndrome increases the risk of cholelithiasis four to five-fold.
In patients with chronic hemolysis, total bile lipid concentration is decreased and the total bilirubin to total lipid ratio is increased. This suggests that the conjugating capacity of hepatocytes is surpassed by the excessive amount of bilirubin resulting from hemolysis. Increased bilirubin monoconjugate and unconjugated bilirubin can precipitate in bile and form complexes with inorganic ions, mostly calcium, and develop into stones.
Patients with hemolytic disorders can also develop biliary sludge, a suspension of precipitated particulate matter in bile dispersed in a viscous, mucin-rich liquid phase . The chemical composition of the precipitates correlates well with the composition of the associated stone and sludge often stands as a harbinger of future stone development.
There is strong data suggesting a benefit in treating cholelithiasis with UDCA and also in preventing gallstone development in various high risk scenarios.
There are several proposed mechanisms for the positive effect of UDCA in primary prevention of pigment stones. Mucoglycoproteins are present in significant amounts in black pigment stones and contribute to the matrix of gallstones. UDCA suppresses the secretion of protein and decreases the levels of various proteins in bile . It has also been suggested that increased colonic bile salt may solubilize unconjugated bilirubin and may prevent calcium complexing.
There is no published data at present on the role of UDCA in prevention and treatment of cholelithiasis in hemolytic diseases. The investigators hypothesise that UDCA can be of benefit to patients with hemolytic disorders in the primary prevention of pigment stones, possible resolution of biliary sludge and existent stones, and reduction of symptomatic episodes of cholelithiasis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The research protocol extends for up to 12 months, during which the participant will attend 3 clinic visits at Shaare Zedek Medical Centre; one at study enrollment, one at 6 months and one at 12 months.
All patients identified will have their medical records reviewed for previous clinical, biochemical or sonographic evidence of gallstones.
Patients will undergo a baseline abdominal ultrasound to assess for biliary sludge, gallstones, or evidence of previous cholecystitis (eg. Thickened gallbladder wall).
All patients will also have blood tested for liver biochemistry, complete blood count, hemolytic screen and fasting lipids.
Participants will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.
Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose.
Each of the in-house visits will include:
- An explicit history taking and review of patient's notes, including review of symptoms, blood tests and previous ultrasounds, other medical conditions and medications.
- Physical examination - including measuring splenic size, assessing for right upper quadrant abdominal tenderness
Blood tests
- Hemoglobin, WBC
- Liver biochemistry: ALT, AST, GGT, ALP (Alkaline Phosphatase), Bilirubin (conjugated and unconjugated), Albumin
- Hemolytic screen: LDH, haptoglobin, reticulocytes
- Fasting lipids: LDL, HDL, Triglycerides
Repeat abdominal ultrasound will be performed at 12 months. The US will specifically relate to the following features in comparison to the baseline US:
- Presence of biliary sludge
- Presence of gallstone: i.Size ii.Number
- Presence of bile duct dilatation
- Presence of gall bladder wall thickening
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel, 91031
- Shaare Zedek Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of a hemolytic disorder including spherocytosis, G6PD deficiency, thalassemia or sickle cell disease.
- Patients with cholelithiasis or bile sludge.
- Age greater than or equal to 4 years.
- Ability to consent to and participate in the study and follow study procedures.
Exclusion Criteria:
- Previous splenectomy (complete or partial)
- Evidence of hemolytic crisis at the time of research enrollment
- Patients with highly symptomatic gallstones who have planned surgical intervention
- Known allergy or intolerance to UDCA
- Existence of concurrent hepatic disease
- Any other laboratory or clinical condition that the investigator considers clinically significant that could impact the outcome of the study or the safety of the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Open Label
32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).
|
Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months. Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lack of sonographic, clinical or biochemical evidence of progression of cholelithiasis or biliary sludge.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in number and severity of episodes of symptomatic gallstones.
Time Frame: 12 months
|
12 months
|
|
Rate of surgical intervention for gallstones disease.
Time Frame: 12 months
|
12 months
|
|
Sonographic improvement (size and number of gallstones, presence of bile sludge, gallbladder wall thickness).
Time Frame: 12 months
|
12 months
|
|
Evaluate tolerability and adverse effects of UDCA therapy in hemolytic disorders.
Time Frame: 12 months
|
including non-specific abdominal discomfort, rash or nausea.
|
12 months
|
Improved biochemical evidence of gallstone disease
Time Frame: 12m
|
reduced gamma-glutamyl-transpeptidase (GGT) and alkaline phosphatase (ALP).
|
12m
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Oren Ledder, MD, Shaare Zedek Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Ursodeoxycholic acid (UDCA)
- White blood cells (WBC)
- Alanine Transaminase (ALT)
- Alkaline Phosphatase (ALP)
- Aspartate Aminotransferase (AST)
- Gamma-Glutamyl Transpeptidase (GGT)
- Lactate dehydrogenase (LDH)
- Low-Density Lipoprotein (LDL)
- High-Density Lipoprotein (HDL)
- Glucose-6-phosphate dehydrogenase (G6PD)
- Ultrasound (US)
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ursolit_Hemolytic disorders
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gallstones
-
Mansoura UniversityCompletedCommon Bile Duct GallstonesEgypt
-
Minia UniversityCompletedGallstones Complicated by CBD StonesEgypt
-
Mansoura UniversityCompletedCommon Bile Duct GallstonesEgypt
-
Seoul National University HospitalUnknownCommon Bile Duct GallstonesKorea, Republic of
-
Hospital General Universitario de AlicanteInstituto de Salud Carlos IIINot yet recruitingAcute Pancreatitis Due to GallstonesSpain
-
Yonsei UniversityTerminatedGallbladder Polyp | Asymptomatic Gallstones Without CholecystitisKorea, Republic of
-
Air Force Military Medical University, ChinaCompletedCommon Bile Duct Gall Stones | Common Bile Duct GallStonesChina
-
Hospital Central "Dr. Ignacio Morones Prieto"CompletedAcute Pancreatitis Due to Gallstones
-
University of Sao Paulo General HospitalBoston Scientific CorporationUnknownCholedocholithiasis | Common Bile Duct GallstonesBrazil
-
University of CagliariUniversità di Napoli Federico II; Università della Campania Luigi VanvitelliNot yet recruitingAcute Pancreatitis | Pancreatitis Biliary | Pancreatitis Relapsing | Pancreatitis Due to GallstonesItaly
Clinical Trials on Ursodeoxycholic Acid
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Hepatitis CJapan
-
University of Sao Paulo General HospitalCompletedPrimary Biliary Cirrhosis | Ursodeoxycholic AcidBrazil
-
University of TennesseeUniversity of Colorado, Denver; Baylor College of Medicine; Children's Hospital... and other collaboratorsCompletedPrimary Sclerosing CholangitisUnited States
-
West China HospitalUnknownHepatitis | Autoimmune | Primary Biliary CholangitisChina
-
HaEmek Medical Center, IsraelUnknown
-
Daewoong Pharmaceutical Co. LTD.CompletedHealthy SubjectKorea, Democratic People's Republic of
-
Institute of Hematology & Blood Diseases HospitalCompleted
-
Turku University HospitalCompletedPregnancy | Intrahepatic CholestasisFinland
-
Nottingham University Hospitals NHS TrustRecruiting
-
Jinling Hospital, ChinaNational Natural Science Foundation of ChinaCompletedShort Bowel SyndromeChina